Tempus at ACC.25: Revolutionizing Cardiovascular Care with AI

Tempus, the AI-driven precision medicine company, is set to make waves at the 2025 American College of Cardiology (ACC) Annual Meeting. Scheduled for March 29-31, 2025, in Chicago, ACC.25 is the premier event for cardiologists and researchers worldwide. Tempus' participation aligns with its mission to empower clinicians with tools that can improve patient outcomes and accelerate the pace of research in cardiovascular care.

Tempus has a proven track record of leveraging AI and precision medicine to advance healthcare. At the 2024 San Antonio Breast Cancer Symposium, Tempus presented research on the economic impact of concurrent tissue and circulating tumor dna molecular profiling in advanced breast cancer patients. This research demonstrated that concurrent testing identified an additional 20% of patients with actionable findings, reducing the need for repeat biopsies and associated adverse events. Similarly, at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting, Tempus presented a study on the clinical validation of a novel multi-omic algorithm for stratifying outcomes in metastatic solid cancer patients treated with immune checkpoint inhibitors. This study aimed to predict patient outcomes to immune checkpoint inhibitors by developing an integrated DNA/RNA ICI biomarker, showcasing Tempus' expertise in using multimodal data to enhance patient care.

Given Tempus' track record, their presentations at ACC.25 are likely to focus on similar advancements in cardiovascular care. For example, they might present research on the use of AI and multimodal data to predict patient outcomes in cardiovascular diseases, identify biomarkers for early detection, or develop personalized treatment plans. Such presentations would demonstrate Tempus' capability to apply their technology to a new field, enhancing their reputation as a leader in precision medicine.

Moreover, Tempus' presentations at ACC.25 would provide a platform to showcase their technology and data-driven insights to a broader audience, including cardiologists, researchers, and industry professionals. This exposure could lead to new collaborations, partnerships, and opportunities for Tempus to expand their market position in the field of precision medicine.



Tempus' participation in ACC.25 is part of its broader strategy in the healthcare and biotech sectors. The meeting features over 300 sessions and a 75th Anniversary Gala, providing ample opportunities for networking and knowledge sharing. This engagement can help Tempus stay at the forefront of cardiovascular research and innovation, further enhancing its reputation as a leader in precision medicine.

In summary, Tempus' participation in the 2025 American College of Cardiology Annual Meeting aligns with its broader strategy in the healthcare and biotech sectors by leveraging its expertise in AI and precision medicine to contribute to the advancement of cardiovascular care. This participation can bring potential benefits such as showcasing innovative solutions, engaging with a global audience, and driving long-term growth through new collaborations and partnerships. Tempus' presentations at ACC.25 are expected to provide specific insights and advancements in cardiovascular care, contributing to the company's reputation and market position in the field of precision medicine. By leveraging their expertise in AI and precision medicine, Tempus can offer valuable contributions to the field of cardiovascular care, enhancing their standing as a leader in precision medicine.